Research

ACTIVE STUDIES

• LADDER (Genentech)
  A 20 month, phase 2, multicenter, randomized, active treatment-controlled study of the efficacy and safety of the ranibizumab port delivery system for sustained delivery of ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

COMPLETED STUDIES

• CLEAR (DigiSight)
  A 3 month, phase 1 and 2 studies on THE CORRELATION OF PAXOS CHECKUP MOBILE APP TO STANDARD IN OFFICE VISUAL ASSESSMENT.

ACTIVE STUDIES

• BOULEVARD (Genentech)
  A multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, parallel group, 28-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with diabetic macular edema.
• HULK (NCRVA and Regeneron)
  A phase I/II, 6 month, open label study of the safety and efficacy of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept for the treatment of diabetic macular edema.
• PALADIN (Alimera)
  A 3 year, phase 4 safety study of IOP signals in patients with DME who are treated with ILUVIEN (fluocinolone acetonide intravitreal implant).

COMPLETED STUDIES

• DEL MAR (Allegro)
  A 6 month, phase 2, multicenter, randomized, controlled, double-masked clinical trial designed to evaluate the safety and exploratory efficacy of Luminate (ALG-1001) as compared to Avastin in the treatment of diabetic macular edema.
• ENDURANCE IIT (NCRVA & Regeneron)
  A 2 year investigator initiated study on the long-term efficacy and safety of intravitreal aflibercept (Eylea) injections for the treatment of diabetic macular edema in subjects who completed the three year VISTA-DME trial.
• PALM (Allergan)
  A phase 2, six month study on the evaluation of Abidipar Pegol (AGN-150998) in patients with decreased vision due to diabetic macular edema.
• PROTOCOL U (DRCR Network)
  A short-term (9 months) evaluation of combination corticosteroid (Ozurdex) + Anti-VEGF (Lucentis) Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy.
• RUBY (Regeneron)
  A 9 month, phase 2, randomized, double-masked study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with diabetic macular edema.
• VISTA (Regeneron)
  A double-masked, randomized, active-controlled, phase 3 study of the efficacy and safety of intravitreal administration of VEGF Trap-Eye in patients with diabetic macular edema.

ACTIVE STUDIES

• PANORAMA (Regeneron)
  A 2 year, Phase 3, multicenter, randomized study of the efficacy and safety of intravitreal aflibercept (Eylea) injection in patients with moderately severe to severe nonproliferative diabetic retinopathy

COMPLETED STUDIES

• Cystoid Macular Edema after Cataract Surgery (Allergan)
  Phase 2 Study of the Dexamethasone Intravitreal Implant (Ozurdex) for combined Pseudophakic Cystoid Edema and Diabetic Macular Edema after cataract surgery.
• DA VINCI (Regeneron)
  Phase 2 study of the safety, tolerability and biological effect of repeated aflibercept (Eylea) in diabetic macular edema.
• DEGAS (Pfizer)
  Phase 2 study of the efficacy and safety of PF-04523655 versus laser in diabetic macular edema.
• PACIFIC (Allegro)
  A 6 month, phase 2, randomized, double-masked, placebo-controlled multicenter clinical trial designed to evaluate the safety and efficacy of Luminate in inducing PVD in subjects with non-proliferative diabetic retinopathy.
• RIDE (Genentech)
  Phase 3 study of the efficacy and safety of Ranibizumab (Lucentis) in diabetic macular edema.
• VISTA (Regeneron)
  A 3 year Phase 3 study of the efficacy, safety and tolerability of aflibercept (Eylea) in patients with diabetic macular edema.

ACTIVE STUDIES

• BEACON (Allergan)
  A 2 year, phase 2 study on the safety and efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with geography atrophy secondary to age-related macular degeneration.
• OMASPECT (Genentech)
  A multicenter, open-label extension study to evaluate the long-term safety and tolerability of lampalizumab in patients with geographic atrophy secondary to age-related macular degeneration who have completed a roche-sponsored study.
• SPECTRI (Genentech)
  A 2 year, phase 3, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of Lampalizumab administered intravitreally to patients with Geographic Atrophy secondary to Age-Related Macular Degeneration.
• TARGETing GA (Santen Inc.)
  Non-interventional, cross-sectional study of Alu RNA measurement and complement factor genotyping of single nucleotide polymorphisms in the complement pathway in patients with geographic atrophy associated with dry age-related macular degeneration.

COMPLETED STUDIES

• ICON (Pfizer)
  A 1 year Phase 2 study examining a monoclonal antibody to decrease the amount of drusen in the eyes seen in people with Dry AMD with an intravenous infusion.
• PREVENT IIT (NCRVA & Genentech)
  A 2 year investigator initiated study on prophylactic Ranibizumab for exudative age-related macular degeneration (AMD) in vulnerable eyes with Non exudative AMD Trial.
• SEATTLE (Acucela)
  A 2 year Phase 2/3 study which aims to reduce the rate of Dry AMD progression with the use of an pill.

ACTIVE STUDIES

• CLKA651X2104 (Novartis)
  A phase 1, 3 month, randomized, single-masked, sham-control, single ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics activity of intravitreal LKA651 in patients with macular edema from diabetic macular edema, neovascular age-related macular degeneration, or retina vein occlusions.

ACTIVE STUDIES

• SAPPHIRE (Clearside Biomedical)
  A phase 3, 12 month, randomized, masked controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion.
• SCORE2 Long Term Follow-Up Phase (NEI)
  A multicenter, non-interventional extension study to understand the long-term efficacy and safety of anti-VEGF treatments on SCORE2 participants who completed the 12 month parent study.

COMPLETED STUDIES

• BRAVO (Genentech)
  Phase 3 study of the efficacy and safety of ranibizumab (Lucentis) compared to sham injection in Branch Retinal Vein Occlusions.
• COPERNICUS (Regeneron)
  Phase 3 study of the safety, tolerability and biological effect of aflibercept (Eylea) for Central Retinal Vein Occlusions.
• CRUISE (Genentech)
  Phase 3 study of the efficacy and safety of ranibizumab (Lucentis) compared to sham injection in Central Retinal Vein Occlusions.
• GENEVA (Allergan)
  Phase 3 study of the efficacy of the Dexamethasone Intravitreal Implant (Ozurdex) in Retinal Vein Occlusions.
• ICON (ICON Biosciences)
  Phase 1 open label dose escalation study of the safety and tolerability of a sustained release Intravitreal Liquid Drug Delivery using Triamcinolone Acetonide.
• NEWTON (NCRVA and Regeneron)
  A 1 year Prospective study of Aflibercept (Eylea) for previously treated Macular Edema associated with Central Retinal Vein Occlusion.
• SCORE2 (NEI)
  A 1 year study of comparative treatment between bevacizumab (Avastin) and aflibercept (Eylea) for Retinal Vein Occlusion.
• SHORE (Genentech)
  Phase 4 study evaluating different dosing regimens of ranibizumab (Lucentis).
• VIBRANT (Regeneron)
  A 1 year, Phase 3 study of the efficacy, safety and tolerability of aflibercept (Eylea) compared to Laser for the treatment of Branch Retinal Vein Occlusion.

ACTIVE STUDIES

• AZALEA (Clearside Biomedical)
  A phase 3, open-label safety study of suprachoroidal triamcinolone acetonide injectable suspension in patients with non-infectious uveitis.
• MAGNOLIA (Clearside Biomedical)
  A multicenter, non-interventional extension study of the safety and efficacy of CLS-TA for the treatment of macular edema associated with non-infectious uveitis.
• PEACHTREE (Clearside Biomedical)
  A 6 month, phase 3, randomized, masked, controlled clinical trial to study the safety and efficacy and safety of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the treatment of subjects with Macular Edema associated with Non-Infectious Uveitis.

COMPLETED STUDIES

• DOGWOOD (Clearside)
  A phase 2, 6 month, randomized, masked, multicenter study to assess the safety and efficacy of CLS-TA, Triamcinolone Acetonide Injectable Suspension in the treatment of subjects with macular edema following uveitis.
• LX211-11 (LUX BIOSCIENCE)
  Phase 3 study of the efficacy and safety of voclosporin for non-infectious uveitis.
• SAKURA (SANTEN)
  A 2 year Phase 3 active treatment controlled study assessing the efficacy and safety of Sirolimus for the treatment of non-infectious uveitis.
• TAHOE (NCRVA and Allergan)
  A 6 month Prospective study of the Dexamethasone Intravitreal Implant (Ozurdex) for Uveitic Macular Edema.
• VITRASERT
  The use of a sustained-release ganciclovir implant to treat Cytomegalovirus Retinitis.

COMPLETED STUDIES

• RELEASE
  Expansile Gas (SF6) for Symptomatic Vitreomacular Adhesion.

ACTIVE STUDIES

• CEDAR (Allergan)
  A 2 year, phase 3 study on the safety and efficacy of Abicipar Pegol (AGN-150998) in patients with neovascular age-related macular degeneration.
• HAWK (Alcon)
  A phase 3, two-year, randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration.
• LADDER (Genentech)
  A 20 month, phase 2, multicenter, randomized, active treatment-controlled study of the efficacy and safety of the ranibizumab port delivery system for sustained delivery of ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
• ONYX (Regeneron)
  A 9 month, randomized, double-masked, active-controlled phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with neovascular age-related macular degeneration.
• SF0166-C-002(SciFluor Life Sciences)
  A Phase I/II,2 month, randomized, double-masked, multicenter clinical trial designed to evaluate the safety and exploratory efficacy of SF0166, topical ophthalmic solution in the treatment of neovascular age-related macular degeneration.

COMPLETED STUDIES

• ANCHOR (Genentech)
  Phase 3 double masked active treatment of the efficacy and safety of ranibizumab (Lucentis) compared to Visudyne for the treatment of Wet AMD.
• CABERNET (Neovista)
  Phase 3 study for the use of radiation with the Epi-Rad 90 system to treat Wet AMD.
• CAPELLA (Regeneron)
  A 1 year, phase2, double-masked, randomized, controlled, multiple-dose, regimen-ranging study of the efficacy and safety of intravitreal REGN2176-3 in patients with neovascular age-related macular degeneration.
• ECLIPSE (Ophthotech)
  A 2 year Phase 3 study to determine the safety and efficacy of E10030 (Fovista) in combination with ranibizumab (Lucentis) compared to ranibizumab (Lucentis) monotherapy in Wet AMD.
• EMERGE (Iconic Therapeutics)
  A 6 month, phase 2, randomized, double-masked, multicenter, active-controlled study evaluating administration of repeated intravitreal doses of hI-con1 in patients with choroidal neovascularization secondary to age-related macular degeneration.
• HARBOR (Genentech)
  Phase 3 randomized treatment study of the efficacy and safety of different doses of ranibizumab (Lucentis) administered monthly or as needed.
• HORIZON (Genentech)
  Follow up study to evaluate the safety and tolerability of ranibizumab (Lucentis).
• MARINA (Genentech)
  Phase 3 double masked active treatment controlled study of the efficacy and safety of ranibizumab (Lucentis).
• NEXUS (Lpath)
  A 9 month Phase 2A study that is evaluating ISONEP as either monotherapy or adjunctive therapy to ranibizumab (Lucentis), bevacizumab (Avastin) or aflibercept (Eylea).
• OPH1004 (Ophthotech)
  A 2 year, phase2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of FOVISTA (anti PDGF-B pegylated aptamer) administered in combination with either Avastin or Eylea compared to Avastion or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration.
• OSPREY (Alcon)
  A 1 year Phase 2 study that will determine the safety, tolerability and efficacy of ESBA 1008 vs aflibercept (Eylea) in Wet AMD.
• OWL (Alcon)
  A 2 month Phase 2 study to evaluate the effect of ESBA 1008 applied by Microvolume Injection or Infusion in Wet AMD.
• PAVE (Santen)
  A 3 month, phase 1, open-label, dose-escalating, sequential-cohort study assessing the safety, tolerability, immunogenicity, and bioactivity of a single intravitreal injection of DE-122 injectable solution for the treatment of refractory exudative age-related macular degeneration.
• REACH Stage 2 (Allergan)
  Phase 2 study of the safety and efficacy of AGN-150998 versus ranibizumab (Lucentis) in treatment-naive patients with advanced AMD.
• REACH Stage 3 (Allergan)
  A 6 month Phase 2 study of the safety and efficacy of AGN-150998 vs ranibizumab (Lucentis) in treatment-naive patients with Wet AMD.
• RESCUE (NCRVA & Genentech)
  A 1 year Study evaluating ranibizumab (Lucentis) in Wet AMD patients previously treated with bevacizumab (Avastin) AND aflibercept (Eylea).
• SAILOR (Genentech)
  A comparative study evaluating the different doses of ranibizumab (Lucentis).
• SEE (Alcon)
  Phase 2 study of the safety, tolerability and efficacy of ESBA 1008 versus ranibizumab (Lucentis) in advanced AMD.
• TAP (Novartis)
  Phase 3 study of the efficacy and safety of Verteporfin with Photodynamic Therapy for the treatment of Wet AMD.
• VIEW (Regeneron)
  Phase 3 Study of the efficacy, tolerability and safety of repeated doses of aflibercept (Eylea).
• VIEW EXTENSION (Regeneron)
  Follow Up study for the patients treated with aflibercept (Eylea) for Wet AMD in the VIEW study.